



**Date: 27<sup>th</sup> November, 2024**

**To,**  
**BSE Ltd.,**  
**Listing Department,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street - Fort,  
Mumbai - 400 001

**Scrip Code: 539730**

Dear Sir/ Madam,

**Sub.: Press Release**

Please find enclosed press release titled "**Fredun Pharmaceuticals Limited Launch Advanced Functional Foods Plant, Boosting Pet Health and Nutrition**" issued by Fredun Pharmaceuticals Limited.

Thanking you,

Yours truly,

For **Fredun Pharmaceuticals Limited**

**Jinkal Soni**  
**Company Secretary and Compliance Officer**

**Encl.**



## **Fredun Pharmaceuticals Limited to Launch Advanced Functional Foods Plant, Boosting Pet Health and Nutrition**

**Mumbai, India, 27th November 2024:** Fredun Pharmaceuticals Limited (BSE: 539730), a leading provider of Pharmaceuticals and innovative healthcare solutions for veterinary applications. Fredun Pharmaceuticals is coming up with a cutting-edge manufacturing facility in Palghar, Maharashtra, which will be dedicated to the production of functional foods for pets. Conceptualized and construction is underway, it will begin operations by the third quarter of FY26, this plant is poised to play a crucial role in addressing the nutritional needs and chronic health concerns of pets in India.

As pet ownership in India evolves, pet parents are becoming increasingly aware of the importance of their pet's health and the impact of nutrition on chronic diseases. Functional foods are emerging as a key component in preventing diet-related illnesses and ensuring a healthier future for pets and their families. Fredun Pharmaceuticals functional food factory is not only equipped with cutting-edge technology but will also focus on manufacturing products to prevent chronic diseases, such as heart disease, diabetes, and certain cancers.

The new facility marks a significant milestone for Fredun Pharmaceuticals as it expands its footprint in the rapidly growing pet care industry in India. With this strategic move, Fredun is poised to become one of the pioneers in the market, providing high-quality, in-house manufactured functional foods designed to meet the nutritional needs of pets. The factory is being constructed with the aim of achieving the highest accreditations in the industry, positioning it as a premier source for top veterinary companies worldwide. While prioritizing the production of Fredun Brands, the facility will also serve white labeling clients for both the domestic and export markets, showcasing the company's versatility and commitment to quality.

The pet care industry in India has witnessed exponential growth, and Fredun Pharmaceuticals is strategically positioned to capitalize on this trend. The company's investment in the new plant is expected to significantly contribute to the growth of its pet care segment, further strengthening its market position.

***Commenting on the Development, Mr. Fredun Medhora, Managing Director, said: "Our new functional food factory will not only be state-of-the-art but will also concentrate on crafting products that safeguard against chronic diseases, shaping a healthier tomorrow for pets and their owners. We recognize the evolving needs of Indian pet parents and are committed to meeting these with our innovative solutions. Machinery procurement is already in progress, and we are on track to be fully operational by Q3 FY26. This expansion is not just about growth; it's about our responsibility to pet health and the trust that pet parents place in us."***

## About Fredun Pharmaceuticals Limited:

Fredun Pharmaceuticals Limited, healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company's objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.

## For more information, please contact:

---

### Fredun Pharmaceuticals Limited

Fredun Medhora

[investing@fredungroup.com](mailto:investing@fredungroup.com)

### Ernst & Young LLP

Abhishek Bhatt

[Abhishek.Bhatt3@in.ey.com](mailto:Abhishek.Bhatt3@in.ey.com)

---

## DISCLAIMER:

Certain statements in this document that are not historical facts are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political, or economic developments, industry risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Fredun Pharmaceuticals Limited will not be responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

---